Most Recent Posts
Speaking about the biopharmaceutical sector's presence in Massachusetts, Governor Deval Patrick discussed the Commonwealth's Life Sciences Initiative, a 10-year, $1 billion program intended to "spur private investment in innovation."
Since its launch, the program has seen every dollar of public investment attract three dollars in private investment, he said. The effect has been significant, driving job growth and spurring the state's already-strong biosciences cluster.
In his opening address today, Sanofi CEO Christopher Viehbacher - speaking as the PhRMA chairman - explained why our annual meeting is being held this year in Boston: "Boston wasn't chosen at random. We're investing in R&D here. We've got some of the top world-class hospitals and universities here. The Milken Institute has consistently ranked Massachusetts as the leader of medical research and innovation in America."
There's nothing more important for a patient than hope - especially for patients faced with a cancer diagnosis. And when faced with a choice between a treatment that offers a shot at longer-term survival vs. a treatment that guarantees a shorter survival gain, cancer patients take the gamble and choose hope.
These findings may not sound surprising. But what is surprising is that our current models for valuing new treatments do a very poor job recognizing this.
We've traveled north to Boston for PhRMA's Annual Meeting, which begins today. My excellent colleague Christian has been doing some interviews leading up to our meeting and giving details about how to engage, but I wanted to give you all a reminder that our Website will be a great resource for those of you who aren't going to be able to join us.
Our guest post comes from Dennis Urbaniak, Vice President, U.S. Diabetes at Sanofi US.
Tomorrow, attendees at the PhRMA Annual Meeting will be discussing ways of improving health through innovation. I wanted to share some thoughts on this important topic as it relates to diabetes.
I'm blogging from the road this week, from the highly energized and hyper-organized National Prescription Drug Abuse Summit, sponsored by the well-known Kentucky organization, UNITE.
In my ongoing conversations about the upcoming PhRMA Annual Meeting, I was very fortunate to spend a few moments with Frank Oldham, the President and CEO of NAPWA. Frank is the model of a patient advocate. He has lived the struggles of the people he represents and is now using his voice and experience to fight for everyone living with HIV/AIDS. "We want people living with HIV to have the best possible care and treatment services as well as the best quality of life they can have," he says.
As we've been discussing here on The Catalyst, PhRMA will host its 2012 Annual Meeting this week on April 12 and 13 in Boston ("Making Medicines Do More"). We'll be bringing together industry CEOs, patient and advocacy groups, and PhRMA staff in a series of panels and group discussions to explore major issues and trends facing our industry.
Recently, I was lucky to catch up with Jim Firman, President and CEO of the National Council on Aging (NCOA), and discuss PhRMA's upcoming Annual Meeting. Jim and I have been working with each other for more than 8 years., having both worked on programs to help increase access to medicine for American's most vulnerable patients.
Happy birthday, PPA.
Seven years ago, PhRMA launched the Partnership for Prescription Assistance. Since then, more than 7 million patients have been matched through the PPA with programs that could help them get their medicines for free or nearly free. Like I do on my own birthday, I'd like to take a moment to look back at how far we've come and be proud of what we've achieved.
Today I read a great story about a police captain in the Royal Canadian Mounted Policy (RCMP) who began issuing "positive tickets" when he saw kids doing something right. The gentleman wrote a book about his theory of rewarding good behavior as well as enforcing bad, and changing the role of the police force and their work with children in a community.
PhRMA's Annual Meeting is right around the corner. As you've seen in a previous post by our CEO John Castellani, this year's meeting "is appropriately titled 'Making Medicines do More,' and its goal is to better tell the story of America's biopharmaceutical research industry." We are really looking forward to the discussions in the conference rooms and online.